2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Lactate Dehydrogenase

Lactate Dehydrogenase

LDH

Lactate Dehydrogenase

Related Products

PDF 0.33 MB

Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+. LDH is comprised of two major subunits, LDH-A and LDH-B, which can assemble into five different isoenzymes (LDH1, LDH2, LDH3, LDH4, and LDH5).

LDH-A is also known as the M subunit as it is predominantly found in skeletal muscle, and LDH-B is also known as the H subunit as it is predominantly found in the heart. LDH-A is a vital metabolic enzyme that is associated with cancer development, invasion, and metastasis. LDH-A is also the key player of the Warburg effect. LDH-A has been reported to correlate with clinicopathologic characteristics and survival outcome of multiple cancers. The inhibition of LDH-A has an anti-proliferative effect on primary breast tumors. LDH-B is a crucial glycolytic enzyme that catalyses conversion of lactate and NAD+ to pyruvate, NADH and H+. LDHB plays an important role in autophagy in cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W040073S
    Nifurtimox-d4
    		Inhibitor
    Nifurtimox-d4 is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
    Nifurtimox-d<sub>4</sub>
  • HY-154866
    Anticancer agent 122
    		Inhibitor
    Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research.
    Anticancer agent 122
  • HY-180830
    NLRP3-IN-86
    		Inhibitor
    NLRP3-IN-86 (Compound 8a), a derivative of Songorine (HY-N2080), is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS (HY-D1056)- and Nigericin (HY-127019)-stimulated lactate dehydrogenase (LDH) release (IC50 = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation.
    NLRP3-IN-86
  • HY-173144
    AChE-IN-85
    		Inhibitor
    AChE-IN-85 (Compound 7k) is an AChE inhibitor with an IC50 of 0.083 μM. AChE-IN-85 can inhibit the release of NO, the production of TNF-α and IL-1β, the levels of LDH and ROS, as well as the aggregation of Aβ42. AChE-IN-85 has anti-inflammatory and neuroprotective effects and can be used in the research of diseases such as Alzheimer's disease.
    AChE-IN-85
  • HY-168733
    LDHA-IN-9
    		Inhibitor
    LDHA-IN-9 (Compound 1g) is an inhibitor for LDH-A with an IC50 of 25 nM. LDHA-IN-9 inhibits the proliferation of DLD-1 cell (GI50 of 27 μM) through apoptosis induction. LDHA-IN-9 exhibits antitumor activity in mouse model without significant toxicity (25 mg/kg).
    LDHA-IN-9
  • HY-182027
    Antibacterial agent 330
    		Inhibitor
    Antibacterial agent 330 is an antibacterial agent. Antibacterial agent 330 triggers ROS accumulation, forms DNA supramolecular complex by intercalation to block DNA replication and inhibits LDH to
    disturb metabolism, and further prompts bacterial cell rupture to induce the leakage of intracellular content, ultimately causing bacterial death. Antibacterial agent 330 displays antibacterial activity and promotes wound healing in both G. Mellonella larval and murine wound infection models. Antibacterial agent 330 can be used for the research of bacterial infections.
    Antibacterial agent 330
  • HY-16964
    LDHA-IN-1
    		Inhibitor
    LDHA-IN-1 is a selective, competitive LDH-A inhibitor, with Ki values of 8.9 μM (NADH assay) and 4.7 μM (Pyruvate assay) against hLDH-A. LDHA-IN-1 inhibits cancer cell proliferation under hypoxic conditions. LDHA-IN-1 can be used in the research of ovarian cancer, colorectal cancer, mesothelioma and pancreatic cancer.
    LDHA-IN-1
  • HY-162627
    LDHA-IN-6
    		Inhibitor
    LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC50 of 46 nM. LDHA-IN-6 has antitumor activity.
    LDHA-IN-6
  • HY-113486S1
    lathosterol-d7
    		Inhibitor
    lathosterol-d7 is deuterium labeled Lathosterol (HY-113486). Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases LDH. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury.
    lathosterol-d<sub>7</sub>
  • HY-179027
    LDH-IN-5
    		Inhibitor
    LDH-IN-5 is a Lactate Dehydrogenase (LDH) inhibitor with neuroprotective activity. LDH-IN-5 can inhibit cell apoptosis, reduce ROS, MDA production and increases superoxide dismutase (SOD) activity. LDH-IN-5 can be used for the research of neurological disease, such as ischemic stroke.
    LDH-IN-5
  • HY-178461
    LDHA-IN-10
    		Inhibitor
    LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC50 value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC).
    LDHA-IN-10
  • HY-100742AR
    (R)-GNE-140 (Standard)
    		Inhibitor
    (R)-GNE-140 (Standard) is the analytical standard of (R)-GNE-140 (HY-100742A). This product is intended for research and analytical applications. (R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer.
    (R)-GNE-140 (Standard)
  • HY-181677
    Antibacterial agent 325
    		Inhibitor
    Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection.
    Antibacterial agent 325
  • HY-180151
    Antibacterial agent 306
    		Inhibitor
    Antibacterial agent 306 (Compound 8c), a lactate dehydrogenase inhibitor, is a highly effective antibacterial agent, especially effective against Gram-positive bacteria. Antibacterial agent 306 exhibits MIC against Staphylococcus aureus of as low as 1 μg/mL. Antibacterial agent 306 can not only damage membrane integrity and block the replication of DNA by intercalation, but also make reactive oxygen species (ROS) burst. Antibacterial agent 306 can be used for research on anti-multi-drug resistant bacteria.
    Antibacterial agent 306
  • HY-100742BR
    (S)-GNE-140 (Standard)
    		Inhibitor
    (S)-GNE-140 (Standard) is the analytical standard of (S)-GNE-140 (HY-100742B). This product is intended for research and analytical applications. (S)-GNE-140 (Compound 30-S) is the S-enantiomer of GNE-140 (HY-118241). (S)-GNE-140 is an effective lactate dehydrogenase (LDH) inhibitor, with IC50 values of 55 nM for LDHA and 140 nM for LDHB. (S)-GNE-140 can be used in cancer research.
    (S)-GNE-140 (Standard)
  • HY-100681R
    GSK2837808A (Standard)
    		Inhibitor
    GSK2837808A (Standard) is the analytical standard of GSK2837808A (HY-100681). This product is intended for research and analytical applications. GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A (Standard)
  • HY-180992
    Dual GO/LDHA-IN-1
    		Inhibitor
    Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1.
    Dual GO/LDHA-IN-1
  • HY-W040073R
    Nifurtimox (Standard)
    		Inhibitor
    Nifurtimox (Standard) is the analytical standard of Nifurtimox. This product is intended for research and analytical applications. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
    Nifurtimox (Standard)
  • HY-N6948R
    Linalyl acetate (Standard)
    		Inhibitor
    Linalyl acetate (Standard) is the analytical standard of Linalyl acetate. This product is intended for research and analytical applications. Linalyl acetate is the principal components of many plant essential oils. Linalyl acetate exhibits anti-anxiety, anti-inflammatory, anti-diabetic, anti-stress, and cardiovascular-regulatory effects. Linalyl acetate is orally active.
    Linalyl acetate (Standard)
  • HY-100742R
    GNE-140 racemate (Standard)
    		Inhibitor
    GNE-140 racemate (Standard) is the analytical standard of GNE-140 racemate (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is an external racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B). GNE-140 racemate is also an effective lactate dehydrogenase (LDH) inhibitor.
    GNE-140 racemate (Standard)
Cat. No. Product Name / Synonyms Application Reactivity